Waldencast plc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $272.1M-0.7% YoYTTM through 31 Dec 2025
Net Income -$229.7MTTM through 31 Dec 2025
Free Cash Flow -$16.2MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 67.3% |
| EBITDA Margin | -96.4% |
| Operating Margin | -80.0% |
| Net Margin | -84.4% |
Returns
-53.7%ROE
-33.2%ROA
Balance Sheet Health
Debt / Equity0.33x
Current Ratio1.70x
Net Debt$121.7M
Cash & Equivalents$30.4M
Quality Metrics
Altman Z-Score-1.35
Piotroski F-Score4 / 9
FCF Margin-6.0%
Rule of 40-0.9
Multi-Year Trend
RevenueFY2025: $272.1M
Diluted EPS-$2.01TTMFY2025: $-2.01
Dividend
No dividend
Capital Allocation
Capex Intensity1.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Obagi Medical | $162M | +8.3% | View detailsOn June 1, 2026, Waldencast announced a definitive agreement to sell Obagi Medical to Bridgepoint for up to $460 million to strengthen its balance sheet and focus on Milk Makeup. |
| Milk Makeup | $110.1M | -11.4% | View detailsFollowing the sale of Obagi Medical, Waldencast plans to focus entirely on accelerating the global growth of Milk Makeup. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.